STTK实时信号 | 通过Getagraph.com最大化利润

出售 109610 min ago

@ $8.64

发出时间: 14 Feb 2024 @ 22:30

回报率: 24.71%

上一信号: Feb 14 - 00:22

上一信号: 购买

回报率: -0.97 %

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 01:18):

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States...

Stats
今日成交量	104 511
平均成交量	337 211
市值	512.36M
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.470 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.26
ATR14	$0.0340 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Redmile Group, Llc	Sell	4 425	Common Stock
2024-03-06	Stout Stephen	Buy	6 459	Common Stock
2024-03-06	Stout Stephen	Buy	4 650	Common Stock
2024-03-06	Stout Stephen	Sell	6 459	Common Stock
2024-03-06	Stout Stephen	Sell	4 895	Common Stock

INSIDER POWER
91.85
Last 97 transactions
Buy: 6 048 321 \| Sell: 567 622

音量相关性

長: 0.03 (neutral)

短: 0.29 (neutral)

Signal:(51.286) Neutral

Shattuck Labs, Inc. 相关性

10 最正相关
IPDN	0.931
RMRM	0.926
PALT	0.919
PAIC	0.914
APOP	0.897
SOFIW	0.897
SVAC	0.896
PRCH	0.894
AMAO	0.89
STX	0.888

10 最负相关
MMAC	-0.935
NETE	-0.917
BOCH	-0.91
AMRB	-0.9
DTSS	-0.854
CFV	-0.849
AZTA	-0.833
BCYC	-0.826
EAR	-0.826
AKAM	-0.824

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Shattuck Labs, Inc. 相关性 - 货币/商品

-0.34
( neutral )

-0.29
( neutral )

0.51
( weak )

-0.47
( neutral )

-0.67
( moderate negative )

-0.19
( neutral )

Shattuck Labs, Inc. 财务报表

Annual	2023
营收:	$1.66M
毛利润:	$-2.39M (-143.93 %)
EPS:	$-2.05

FY	2023
营收:	$1.66M
毛利润:	$-2.39M (-143.93 %)
EPS:	$-2.05

FY	2022
营收:	$652 000
毛利润:	$-2.72M (-417.64 %)
EPS:	$-2.37

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.067

Financial Reports:

No articles found.

Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.